| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Not applicable (mixture of dietary fatty acids with multiple metabolic fates). Soya fatty acids are not a pharmacologically targeted drug but function as nutrients and structural components. They are incorporated into cell membrane phospholipids and serve as precursors for bioactive lipid mediators (e.g., eicosanoids). As an excipient, they act as solubilizers, emulsifiers, or drug delivery vehicles.
|
|---|---|
| ln Vitro |
Linoleic acid (a major component) is an essential fatty acid that cannot be synthesized by the human body. It is required for the biosynthesis of arachidonic acid and subsequent eicosanoids (prostaglandins, leukotrienes). Oleic acid (monounsaturated) improves insulin sensitivity and has anti-inflammatory effects in vitro by modulating NF-kappaB signaling.
|
| ln Vivo |
In animal models, soya oil-based lipid emulsions (e.g., Intralipid) are used clinically and experimentally as a parenteral nutrition source. Oral administration of soya fatty acids (1-5 g/kg) in rats increases plasma triglyceride and cholesterol levels and alters hepatic lipid metabolism. Intravenous administration provides essential fatty acids and a high-density energy source for caloric supplementation.
|
| Enzyme Assay |
Not applicable (mixture of natural products). For quality control, the fatty acid composition is analyzed by GC-FID: the sample is methylated using 0.5 M sodium methoxide in methanol (60degC, 10 min). Fatty acid methyl esters (FAMEs) are extracted into hexane and injected onto a fused-silica capillary column (e.g., DB-23, 60 m × 0.25 mm). The oven temperature is programmed: 100degC to 220degC at 5degC/min. Peaks are identified by comparison to retention times of standard FAME mixtures.
|
| Cell Assay |
Various cell types (e.g., HepG2 hepatocytes, RAW 264.7 macrophages, or 3T3-L1 adipocytes) are cultured in DMEM supplemented with 10% FBS. Cells are treated with soya fatty acids (25-200 uM complexed with 0.5% fatty acid-free BSA) for 6-24 h. Lipid accumulation is measured by Oil Red O staining and quantification at 492 nm. Inflammatory markers (TNFalpha, IL-6, MCP-1) are measured in culture supernatants by ELISA.
|
| Animal Protocol |
C57BL/6J mice (8-10 weeks old) are fed a high-fat diet (HFD, 60% kcal from fat, including soya oil) or a control diet (10% kcal from fat) for 8-12 weeks. Body weight and food intake are recorded weekly. At termination, blood is collected for glucose, insulin, and lipid profiling (triglycerides, total cholesterol). Liver, adipose tissue, and muscle are harvested for histology (H&E, Oil Red O) and gene expression analysis by qPCR.
|
| ADME/Pharmacokinetics |
Soya fatty acids are absorbed in the small intestine, packaged into chylomicrons, and transported via lymphatic circulation. In the liver and peripheral tissues, they undergo beta-oxidation or are stored as triglycerides. The terminal half-life is dependent on the specific fatty acid chain length and saturation. As an excipient, they are rapidly cleared from plasma when used intravenously (e.g., Intralipid has an initial half-life of ~15 min).
|
| Toxicity/Toxicokinetics |
Soya fatty acids are considered Generally Recognized as Safe (GRAS) by the FDA. Adverse effects are rare and dose-dependent: when administered intravenously as lipid emulsions, potential side effects include fat overload syndrome (hypertriglyceridemia, hepatomegaly, coagulopathy) and allergic reactions (rare). Oral intake is safe at dietary levels (up to 2 g/kg).
|
| Additional Infomation |
Soya fatty acids are primarily used as a pharmaceutical excipient in lipid-based drug delivery systems (e.g., self-emulsifying drug delivery systems, SEDDS), parenteral nutrition (lipid emulsions), and as a solubilizer for poorly water-soluble drugs (e.g., propofol, etomidate). They also serve as a raw material for the synthesis of soya lecithin and various pharmaceutical-grade lipids (e.g., phosphatidylcholine).
|
| CAS # |
68308-53-2
|
|---|---|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol : ~100 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
